Results 41 to 50 of about 1,247,370 (242)

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Molecular landscape of prostate cancer: implications for current clinical trials. [PDF]

, 2015
Castration-resistant prostate cancer (CRPC) is a lethal disease, and improvement with androgen-deprivation therapy has plateaued. Next-generation sequencing studies have led to significant advances in our understanding of genomic alterations in prostate ...
Ikeda, Sadakatsu, Khemlina, Galina, Kurzrock, Razelle   +2 more
core   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

Clinical metagenomics. [PDF]

, 2019
Clinical metagenomic next-generation sequencing (mNGS), the comprehensive analysis of microbial and host genetic material (DNA and RNA) in samples from patients, is rapidly moving from research to clinical laboratories. This emerging approach is changing
Chiu, Charles Y, Miller, Steven A
core  

Frontiers in Pigment Cell and Melanoma Research

, 2018
We identify emerging frontiers in clinical and basic research of melanocyte biology and its associated biomedical disciplines. We describe challenges and opportunities in clinical and basic research of normal and diseased melanocytes that impact current ...
Birlea, Stanca, Bosenberg, Marcus W., Box, Neil F., Brash, Douglas, Cassidy, Pamela B., Chen, Suzie, D'Orazio, John August, Filipp, Fabian V., Fujita, Mayumi, Goh, Boon-Kee, Herlyn, Meenhard, Indra, Arup K., Larue, Lionel, Leachman, Sancy A., Liu-Smith, Feng, Manga, Prashiela, Montoliu, Lluis, Norris, David A., Poole, Caroline Le, Shellman, Yiqun, Smalley, Keiran S. M., Spritz, Richard A., Sturm, Richard A., Swetter, Susan M., Terzian, Tamara, Wakamatsu, Kazumasa, Weber, Jeffrey S.   +26 more
core   +1 more source

Barriers to Accrual and Enrollment in Brain Tumor Trials [PDF]

, 2019
Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients
Chukwueke, Ugonma N, et al, Hervey-Jumper, Shawn L, Lee, Eudocia Q, Weller, Michael   +4 more
core   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. [PDF]

, 2019
A number of important drugs used to treat cancer-many of which serve as the backbone of modern chemotherapy regimens-have outdated prescribing information in their drug labeling.
Balogh, Erin P, Bindman, Andrew B, Eckhardt, S Gail, Halabi, Susan, Harvey, R Donald, Jaiyesimi, Ishmael, Miksad, Rebecca, Moses, Harold L, Nass, Sharyl J, Schilsky, Richard L, Sun, Steven, Torrente, Josephine M, Warren, Katherine E   +12 more
core   +2 more sources

Evaluating PET-CT in the detection and management of recurrent cervical cancer: Systematic reviews of diagnostic accuracy and subjective elicitation [PDF]

, 2013
Background: Positron emission tomography-computed tomography (PET-CT) is recommended to triage women for exenterative surgery and surveillance after treatment for advanced cervical cancer.
Auguste, P, Barton, P, Borowiack, E, Davenport, C, Guest, P, Khan, K, Kowalska, M, Martin-Hirsch, P, Małysiak, S, Meads, C, Roberts, T, Sundar, S, Zapalska, A   +12 more
core   +1 more source

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately   +11 more
wiley   +1 more source